Absci Corporation

Absci Corporation

ABSI·NASDAQ

$5.94

-6.5%
HealthcareBiotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

At a Glance

Live Snapshot
Market Cap$926.08M
EPS-0.8400
P/E Ratio-7.07
Earnings Date08/11/2026

absi

Research Development Expenses

Last Annual Value

81.42M

3-Year CAGR

11%

5-Year CAGR

48%

10-Year CAGR

34%

Absci Corporation

Absci Corporation Competitors Analysis of research-development-expenses

ABSI · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
81.42M
19.2%12.8%N/A 
RGNX logo
REGENXBIO Inc.
NASDAQ:RGNX
228.30M
-0.6%4.7%17.5%
33.72M
26.8%3.0%1.4%
134.85M
-15.1%10.4%1.2%
174.09M
8.8%0.4%N/A
VSTM logo
Verastem, Inc.
NASDAQ:VSTM
114.60M
23.2%23.8%19.2%
117.00M
-12.7%14.9%N/A
129.62M
7.7%14.2%24.9%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
92.85M
-3.7%4.7%N/A
157.70M
22.3%25.3%N/A
Absci Corporation

Absci Corporation Fair Value Envelope

ABSI · NASDAQ

Our analysis suggests that ABSI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.94, this represents a potential HIDDEN relative to our calculated worth for Absci Corporation.

Intrinsic Value
Current Price: $5.94